Aspen Neuroscience just locked in a $115M Series C, and it lands with the kind of weight you feel through the floorboards. OrbiMed, ARCH Venture Partners, Frazier Life Sciences, and Revelation Partners came in as co-leads, and that is not casual capital. That is the kind of syndicate that only shows up when the science is real, the execution is tight, and the future is starting to look a lot less theoretical. New investors like Kite, a Gilead Co., Balyasny Asset Management, Cormorant Asset Management, and Prebys Ventures joined the round, and the combination feels like an industry chorus saying pay attention.
Aspen Neuroscience built its home in San Diego, but its ambition is bigger than any ZIP code. Co-founders Jeanne F. Loring, Ph.D. and Andrés Bratt Leal, Ph.D. turned a skin cell into a spark that could change how we think about Parkinson’s disease. Today that spark is moving through clinics, showing 45% avg motor improvement in early Phase 1/ Phase 2a data with no major safety issues. Fourteen patients have already been dosed, the FDA Fast Track badge is in place, and the company is preparing for Phase 3 talks in 2026. That is what happens when biology, engineering, and persistence all lock into the same rhythm.
This kind of trajectory does not happen without leaders who know how to guide a science-heavy ship through clinical waters. President and CEO Damien McDevitt, Ph.D. keeps the pace. CMO Edward Wirth III, M.D., Ph.D. brings decades of cell therapy experience. CTO Kim Raineri builds the manufacturing backbone. Chief Regulatory Officer Ana Sousa keeps the regulatory path tight. CSO Xiaokui Zhang, Ph.D. pushes the science forward. SVP Therapeutic Program Lead Lisa Johnson Pratt, M.D. drives the program strategy. CFO Dalen Meeter sharpens the numbers. VP of Process and Analytical Development Thorsten Gorba, Ph.D. scales the system. This is a roster built for real movement, not theoretical potential.
The board reads like biotech’s version of a supergroup. Chairman Faheem Hasnain, Damien McDevitt, Tom Daniel, M.D., Doug Fisher, M.D., Peter Thompson, M.D., Drew Spaventa, Caryn Peterson, and the latest addition, Cindy Perettie from Kite, bring a level of guidance that signals Aspen Neuroscience is thinking about tomorrow’s commercialization as much as today’s clinical data. When strategic investors send someone of Cindy Perettie’s caliber, it usually means the stakes just shifted.
This round fuels the GMP scaling, the automation rollout, the expansion of a pipeline that reaches beyond Parkinson’s, and the push toward a commercial formulation already being used in Cohort 3. Aspen Neuroscience is not trying to slow Parkinson’s. They are trying to replace what it takes. If you are in the Parkinson’s space, the neuro space, or just watching where the next real inflection in medicine might come from, this is one of those moments where the signal gets louder, the room gets quiet, and everyone leans in.
Startups Startup Funding Venture Capital Series C Biotech Healthcare Health Tech Data Data Driven Technology Innovation Tech Ecosystem Startup Ecosystem Hiring Tech Hiring
